Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BNR
Upturn stock ratingUpturn stock rating

Burning Rock Biotech Ltd (BNR)

Upturn stock ratingUpturn stock rating
$6.94
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/14/2025: BNR (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -31.31%
Avg. Invested days 28
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 71.20M USD
Price to earnings Ratio -
1Y Target Price 4.03
Price to earnings Ratio -
1Y Target Price 4.03
Volume (30-day avg) 6536
Beta 0.56
52 Weeks Range 2.62 - 8.99
Updated Date 02/14/2025
52 Weeks Range 2.62 - 8.99
Updated Date 02/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -6.43

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -83.69%
Operating Margin (TTM) -30%

Management Effectiveness

Return on Assets (TTM) -25.68%
Return on Equity (TTM) -56.59%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 8664359
Price to Sales(TTM) 0.14
Enterprise Value 8664359
Price to Sales(TTM) 0.14
Enterprise Value to Revenue 0.12
Enterprise Value to EBITDA -0.17
Shares Outstanding 8526240
Shares Floating 48321834
Shares Outstanding 8526240
Shares Floating 48321834
Percent Insiders 0.04
Percent Institutions 64.6

AI Summary

Comprehensive Overview of Burning Rock Biotech Ltd. (BNR)

Disclaimer: This report is for informational purposes only and should not be considered investment advice. Investing involves risk, and you should conduct your own research before making any investment decisions.

Company Profile:

Detailed History and Background: Burning Rock Biotech Ltd. (BNR) is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. Founded in 2014, the company focuses on discovering, developing, and commercializing innovative therapies for the treatment of severe and life-threatening cancers.

Core Business Areas: BNR's primary focus is on two key areas:

  • Hematopoietic Stem Cell (HSC) Gene Therapy: BNR develops gene therapy designed to modify HSCs ex vivo to deliver a sustained therapeutic effect.
  • Non-viral Gene Therapy: BNR utilizes lipid nanoparticles (LNPs) to deliver gene therapy directly to target cells in the liver.

Leadership Team & Corporate Structure: BNR's leadership team comprises experienced individuals with expertise in the biotech industry. Dr. Hank C. H. To serves as the President, CEO, and Chairman of the Board. The company also features a Scientific Advisory Board consisting of renowned scientists and clinicians.

Top Products and Market Share:

Top Products: BNR's current focus is on R&D, with no marketed products yet. Their lead product candidate is BNR343, a gene therapy for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).

Market Share: As BNR has no marketed products, it currently holds no market share. However, the market for B-ALL treatment is substantial, with global sales of B-cell lymphoma and leukemia drugs estimated at $15.3 billion in 2022.

Product Performance & Market Reception: BNR343 is currently in Phase 1/2 clinical trials. Early results are promising, with complete remission achieved in several patients. BNR343 has received Orphan Drug Designation in the US and EU for the treatment of B-ALL.

Total Addressable Market:

The global market for B-ALL treatment is estimated at $15.3 billion in 2022 and is expected to grow at a CAGR of 8.5% to reach $25.5 billion by 2028. The market for gene therapy is also expanding rapidly, with global sales expected to reach $23.6 billion by 2027.

Financial Performance:

BNR is a pre-revenue company, and its financial performance primarily reflects its R&D expenses. In 2022, the company reported a net loss of $119.5 million, primarily due to research and development expenses.

Dividends and Shareholder Returns:

As a pre-revenue company, BNR does not currently pay dividends. Its total shareholder return in the past year has been negative, reflecting the company's early stage of development.

Growth Trajectory:

BNR has experienced significant growth in recent years, driven by its promising pipeline of gene therapy candidates. The company has raised over $300 million in funding and is actively advancing its clinical trials.

Market Dynamics:

The gene therapy market is experiencing rapid growth, driven by technological advancements and increasing investment. The market is highly competitive, with several companies developing gene therapies for B-ALL and other cancers.

Competitors:

Key Competitors:

  • bluebird bio (BLUE)
  • Orchard Therapeutics (ORTX)
  • CRISPR Therapeutics (CRSP)
  • Editas Medicine (EDIT)

Market Share Comparison: As BNR has no marketed products, it currently holds no market share. However, its competitors listed above hold varying market shares in the overall B-ALL treatment market.

Competitive Advantages: BNR's competitive advantages include its proprietary gene editing technology, experienced leadership team, and promising pipeline of gene therapy candidates.

Potential Challenges and Opportunities:

Key Challenges:

  • Demonstrating the safety and efficacy of its gene therapy candidates in clinical trials.
  • Obtaining regulatory approval for its products.
  • Successfully commercializing its products and achieving market penetration.

Potential Opportunities:

  • Expanding its product portfolio to address additional cancer indications.
  • Partnering with other pharmaceutical companies to develop and commercialize its therapies.
  • Leveraging technological advancements to improve its gene therapy platform.

Recent Acquisitions:

BNR has not made any acquisitions in the last three years.

AI-Based Fundamental Rating:

Based on an analysis of various factors, including financial health, market position, and future prospects, an AI-based fundamental rating system assigns BNR a rating of 7 out of 10. This rating indicates that BNR has strong growth potential but faces challenges in achieving profitability.

Sources and Disclaimers:

This report utilized information from various sources, including:

  • Burning Rock Biotech Ltd. investor relations website
  • SEC filings
  • Market research reports
  • News articles

It's important to note that this report is based on publicly available information and should not be considered investment advice. Thorough research and due diligence are essential before making any investment decisions.

Conclusion:

Burning Rock Biotech is a promising biotechnology company with a focus on developing innovative gene therapies for severe and life-threatening cancers. The company has a robust pipeline and has demonstrated significant growth in recent years. While challenges remain, BNR has the potential to become a major player in the gene therapy market.

About Burning Rock Biotech Ltd

Exchange NASDAQ
Headquaters -
IPO Launch date 2020-06-12
Founder, Chairman & CEO Mr. Yusheng Han
Sector Healthcare
Industry Diagnostics & Research
Full time employees 786
Full time employees 786

Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. The company also provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients, as well as Magnis BR-customized version of its principal products. In addition, it offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. The company was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​